IKCEST

Case Reports in Medicine | Vol.2010, Issue. | 2017-05-29 | Pages

Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides

Abstract

Histone deacetylase (HDAC) inhibitors have shown significant activity in the treatment of cutaneous T-cell lymphomas (CTCL). The epigenetic alterations of CTCL not only are limited to altered histone acetylation but also include aberrant DNA gene methylation hence, the combination of an HDAC inhibitor with a DNA demethylating agent is a promising therapy to be tested. Here we report a mycosis fungoides patient having a dramatic response to hydralazine and valproate, two repositioned drugs as HDAC and DNA methylation inhibitors, respectively.

Original Text (This is the original text for your reference.)

Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides

+More

Keywords

altered histone acetylation ctcl aberrant dna gene methylation dna demethylating agent deacetylase hdac inhibitors tcell lymphomas epigenetic alterations

Cite this article

APA

MLA

Chicago

,.Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides. 2010 (),.

References

Disclaimer: The translated content is provided by third-party translation service providers, and IKCEST shall not assume any responsibility for the accuracy and legality of the content.